Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 164

1.

Development of a secondary autoimmune disorder after hematopoietic stem cell transplantation for autoimmune diseases: role of conditioning regimen used.

Loh Y, Oyama Y, Statkute L, Quigley K, Yaung K, Gonda E, Barr W, Jovanovic B, Craig R, Stefoski D, Cohen B, Burt RK.

Blood. 2007 Mar 15;109(6):2643-548. Epub 2006 Nov 21.

2.

[A prospective and randomized study of two conditioning regimens in treatment of severe systemic autoimmune diseases with autologous peripheral blood stem cell transplantation].

Zhang W, Zhou DB, Zhao Y, Leng XM, Zhang JP, Jiang Y, Jiao L, Wang SJ, Duan MH, Tang FL, Shen T.

Zhonghua Yi Xue Za Zhi. 2007 Jun 26;87(24):1689-92. Chinese.

PMID:
17825150
3.

Intense immunosuppressive therapy followed by autologous peripheral blood selected progenitor cell reinfusion for severe autoimmune disease.

Musso M, Porretto F, Crescimanno A, Bondi F, Polizzi V, Scalone R.

Am J Hematol. 2001 Feb;66(2):75-9.

4.

A pilot trial for severe, refractory systemic autoimmune disease with stem cell transplantation.

Leng XM, Zhao Y, Zhou DB, Situ H, Li TS, Shen T, Zhao YQ, Zeng XF, Zhang FC, Dong Y, Tang FL.

Chin Med Sci J. 2005 Sep;20(3):159-65.

PMID:
16261884
5.

[Hematopoietic stem cell transplantation in autoimmune diseases].

Albarracín F, López Meiller MJ, Naswetter G, Longoni H.

Medicina (B Aires). 2008;68(2):153-63. Spanish. Erratum in: Medicina (B Aires). 2008;68(3):267. Meier, María José López [corrected to Meiller, María José López].

PMID:
18499968
6.

Autologous peripheral blood stem cell transplantation for severe multiple sclerosis.

Su L, Xu J, Ji BX, Wan SG, Lu CY, Dong HQ, Yu YY, Lu DP.

Int J Hematol. 2006 Oct;84(3):276-81.

PMID:
17050205
7.

The rationale behind autologous autoimmune hematopoietic stem cell transplant conditioning regimens: concerns over the use of total-body irradiation in systemic sclerosis.

Burt RK, Patel D, Thomas J, Yeager A, Traynor A, Heipe F, Arnold R, Marmont A, Collier D, Glatstein E, Snowden J.

Bone Marrow Transplant. 2004 Nov;34(9):745-51. Review. Erratum in: Bone Marrow Transplant. 2005 Jan;35(1):105.

PMID:
15361910
8.

Mobilization, harvesting and selection of peripheral blood stem cells in patients with autoimmune diseases undergoing autologous hematopoietic stem cell transplantation.

Statkute L, Verda L, Oyama Y, Traynor A, Villa M, Shook T, Clifton R, Jovanovic B, Satkus J, Loh Y, Quigley K, Yaung K, Gonda E, Krosnjar N, Spahovic D, Burt RK.

Bone Marrow Transplant. 2007 Mar;39(6):317-29. Epub 2007 Feb 5.

PMID:
17277794
9.

Autoimmune disease after autologous hematopoietic stem cell transplantation.

Bohgaki T, Atsumi T, Koike T.

Autoimmun Rev. 2008 Jan;7(3):198-203. doi: 10.1016/j.autrev.2007.11.005. Epub 2007 Dec 3. Review.

PMID:
18190878
10.

Autologous hematopoietic stem cell transplantation for childhood autoimmune disease.

Milanetti F, Abinun M, Voltarelli JC, Burt RK.

Pediatr Clin North Am. 2010 Feb;57(1):239-71. doi: 10.1016/j.pcl.2009.12.003. Review.

PMID:
20307720
11.

Impact of T cell chimerism on clinical outcome in 117 patients who underwent allogeneic stem cell transplantation with a busulfan-containing reduced-intensity conditioning regimen.

Saito B, Fukuda T, Yokoyama H, Kurosawa S, Takahashi T, Fuji S, Takahashi N, Tajima K, Kim SW, Mori S, Tanosaki R, Takaue Y, Heike Y.

Biol Blood Marrow Transplant. 2008 Oct;14(10):1148-55. doi: 10.1016/j.bbmt.2008.07.013.

12.

Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.

Chen XH, Zhang C, Zhang X, Gao L, Gao L, Kong PY, Peng XG, Qi DG, Sun AH, Zeng DF, Liu H, Gong Y, Wang QY.

Biol Blood Marrow Transplant. 2009 Feb;15(2):266-73. doi: 10.1016/j.bbmt.2008.11.029. Erratum in: Biol Blood Marrow Transplant. 2009 Apr;15(4):521.

13.

[Alterations in coagulation in patients during transplant conditioning regimen before allogeneic hematopoietic stem cell transplantation].

Jiang Q, Huang XJ, Liu KY, Chen H, Chen YH, Gao ZY, Lu DP.

Zhonghua Xue Ye Xue Za Zhi. 2006 Mar;27(3):173-7. Chinese.

PMID:
16792919
14.

Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma.

Benekli M, Smiley SL, Younis T, Czuczman MS, Hernandez-Ilizaliturri F, Bambach B, Battiwalla M, Padmanabhan S, McCarthy PL Jr, Hahn T.

Bone Marrow Transplant. 2008 Apr;41(7):613-9. Epub 2007 Dec 10.

PMID:
18071290
15.

Non-myeloablative stem cell transplantation for autoimmune diseases.

Burt RK, Verda L, Oyama Y, Statkute L, Slavin S.

Springer Semin Immunopathol. 2004 Nov;26(1-2):57-69. Epub 2004 Jul 29. Review.

PMID:
15549303
16.

High incidence of invasive aspergillosis associated with intestinal graft-versus-host disease following nonmyeloablative transplantation.

Labbé AC, Su SH, Laverdière M, Pépin J, Patiño C, Cohen S, Kiss T, Lachance S, Sauvageau G, Busque L, Roy DC, Roy J.

Biol Blood Marrow Transplant. 2007 Oct;13(10):1192-200. Epub 2007 Aug 3.

17.

Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.

Kim HJ, Min WS, Cho BS, Eom KS, Kim YJ, Min CK, Lee S, Cho SG, Jin JY, Lee JW, Kim CC.

Biol Blood Marrow Transplant. 2009 Jun;15(6):704-17. doi: 10.1016/j.bbmt.2009.02.010. Epub 2009 Apr 9.

18.

Secondary autoimmune diseases occurring after HSCT for an autoimmune disease: a retrospective study of the EBMT Autoimmune Disease Working Party.

Daikeler T, Labopin M, Di Gioia M, Abinun M, Alexander T, Miniati I, Gualandi F, Fassas A, Martin T, Schwarze CP, Wulffraat N, Buch M, Sampol A, Carreras E, Dubois B, Gruhn B, Güngör T, Pohlreich D, Schuerwegh A, Snarski E, Snowden J, Veys P, Fasth A, Lenhoff S, Messina C, Voswinkel J, Badoglio M, Henes J, Launay D, Tyndall A, Gluckman E, Farge D; EBMT Autoimmune Disease Working Party.

Blood. 2011 Aug 11;118(6):1693-8. doi: 10.1182/blood-2011-02-336156. Epub 2011 May 19.

19.

Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire.

Michallet M, Le QH, Mohty M, Prébet T, Nicolini F, Boiron JM, Esperou H, Attal M, Milpied N, Lioure B, Bordigoni P, Yakoub-Agha I, Bourhis JH, Rio B, Deconinck E, Renaud M, Chir Z, Blaise D.

Exp Hematol. 2008 May;36(5):535-44. doi: 10.1016/j.exphem.2008.01.017. Epub 2008 Mar 17.

PMID:
18346838
20.

Recurrence of autoimmune disease after autologous peripheral blood stem cell transplantation for multiple myeloma.

Isshiki I, Okamoto S, Kakimoto T, Chen CK, Mori T, Yokoyama K, Hattori Y, Ikeda Y.

Int J Hematol. 2006 Nov;84(4):354-8.

PMID:
17118763

Supplemental Content

Support Center